Makers of sartan angiotensin II receptor blocker medications have been given a two year deadline to ensure their products are not contaminated with potentially carcinogenic N-nitroso impurities. Following a 2018 scare in the US when the FDA found several generic ARB medicines contained nitrosamine impurities the Therapeutic Goods Administration has told Australian suppliers that they ...
Sartan makers given 2 years to ensure they’re free of impurities
By Michael Woodhead
18 Sep 2019